Literature DB >> 954349

Pharmacokinetics of naproxen overdoses.

R Runkel, M D Chaplin, H Sevelius, E Ortega, E Segre.   

Abstract

In earlier safety studies, naproxen, 600 mg three times daily, was administered to healthy subject without significant adverse effects. Another study demonstrated that single doses of 500 to 900 mg resulted in accelerated renal clearance and a nonlinear naproxen plasma level response after the higher doses. Our report describes the pharmacokinetics of naproxen when administered in single doses of 1, 2, 3, or 4 gm (up to eight times the clinically effective dose in rheumatoid arthritis) to healthy subjects. An increase in urinary excretion rate and continuation of the previously documented nonlinear plasma level response were observed. There were no signs that capacity to conjugate or to excrete the drug was exceeded. There were no adverse effects.

Entities:  

Mesh:

Substances:

Year:  1976        PMID: 954349     DOI: 10.1002/cpt1976203269

Source DB:  PubMed          Journal:  Clin Pharmacol Ther        ISSN: 0009-9236            Impact factor:   6.875


  21 in total

Review 1.  Biowaivers for oral immediate-release products: implications of linear pharmacokinetics.

Authors:  Fried Faassen; Herman Vromans
Journal:  Clin Pharmacokinet       Date:  2004       Impact factor: 6.447

2.  Dose-dependent pharmacokinetics of MK-417, a potent carbonic anhydrase inhibitor, in experimental polycythemic and anemic rats.

Authors:  J H Lin; I W Chen; F A deLuna
Journal:  Pharm Res       Date:  1991-05       Impact factor: 4.200

3.  Serum protein binding of nonsteroidal antiinflammatory drugs: a comparative study.

Authors:  O Borgå; B Borgå
Journal:  J Pharmacokinet Biopharm       Date:  1997-02

Review 4.  Pharmacokinetic drug interactions with nonsteroidal anti-inflammatory drugs.

Authors:  R K Verbeeck
Journal:  Clin Pharmacokinet       Date:  1990-07       Impact factor: 6.447

Review 5.  Toxic effects of nonsteroidal anti-inflammatory drugs in overdose. An overview of recent evidence on clinical effects and dose-response relationships.

Authors:  S C Smolinske; A H Hall; S A Vandenberg; D G Spoerke; P V McBride
Journal:  Drug Saf       Date:  1990 Jul-Aug       Impact factor: 5.606

6.  S-Naproxen and desmethylnaproxen glucuronidation by human liver microsomes and recombinant human UDP-glucuronosyltransferases (UGT): role of UGT2B7 in the elimination of naproxen.

Authors:  Kushari Bowalgaha; David J Elliot; Peter I Mackenzie; Kathleen M Knights; Stellan Swedmark; John O Miners
Journal:  Br J Clin Pharmacol       Date:  2005-10       Impact factor: 4.335

7.  Hypoalbuminaemia and naproxen pharmacokinetics in a patient with rheumatoid arthritis.

Authors:  F A Van den Ouweland; F W Gribnau; Y Tan; C A Van Ginneken; L B Van de Putte
Journal:  Clin Pharmacokinet       Date:  1986 Nov-Dec       Impact factor: 6.447

Review 8.  Acute poisoning due to non-steroidal anti-inflammatory drugs. Clinical features and management.

Authors:  J A Vale; T J Meredith
Journal:  Med Toxicol       Date:  1986 Jan-Feb

9.  Jaundice associated with naproxen.

Authors:  R M Victorino; J C Silveira; A Baptista; M C de Moura
Journal:  Postgrad Med J       Date:  1980-05       Impact factor: 2.401

Review 10.  Protein binding as a primary determinant of the clinical pharmacokinetic properties of non-steroidal anti-inflammatory drugs.

Authors:  J H Lin; D M Cocchetto; D E Duggan
Journal:  Clin Pharmacokinet       Date:  1987-06       Impact factor: 6.447

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.